Investment Rating - The report maintains an "Overweight" rating for the pet economy sector, highlighting its rapid growth during the Spring Festival [4][7]. Core Insights - The pet consumption during the Spring Festival has seen significant growth, with a 20%+ year-on-year increase in searches for "New Year pet gift boxes" on Tmall. The sales of pet clothing surged by 330%, and pet New Year's dinners increased by 290% [7]. - The report emphasizes the comprehensive nature of pet services, with a 46% month-on-month increase in pet boarding demand. The expansion of pet transport services on high-speed trains and airlines is also noted [7]. - Upcoming pet exhibitions in March are expected to further stimulate market interest, with major brands likely to launch new products [7]. Summary by Sections Important Industry Data Overview - The agricultural sector index stands at 2,858.1, with a year-on-year increase of 14.28%. The wholesale price index for agricultural products is at 129.6, reflecting a 4.95% year-on-year increase [10]. - The average price of live pigs is 12.3 yuan/kg, down 15.81% year-on-year, while the average price of piglets is 471.0 yuan/head, down 25.24% year-on-year [10]. Pig Farming Sector - The report anticipates a seasonal decline in pig prices post-Spring Festival, with expectations of low prices leading to potential losses in farming [5][12]. - Recommended stocks in the pig farming sector include Muyuan Foods and Wens Foodstuffs, with additional recommendations in the agricultural product supply chain [5]. Poultry Sector - The report discusses the white feather broiler market, noting a decrease in chick prices and stable prices for broiler meat [19][20]. - The average price of broiler chicks is reported at 2.4 yuan/chick, with a 4.35% increase month-on-month [10]. Feed Sector - The report indicates stable feed prices, with corn prices at 2,372.2 yuan/ton and soybean meal prices at 3,167.7 yuan/ton [10][30]. - The analysis highlights the fluctuations in import prices for soybeans and corn, impacting the feed sector [32]. Key Company Profit Forecasts and Valuations - The report provides earnings per share (EPS) forecasts for key companies, with Muyuan Foods projected at 2.54 yuan for 2025 and 4.81 yuan for 2026, maintaining an "Overweight" rating [36]. - Other companies such as Wens Foodstuffs and Petty Holdings also receive "Overweight" ratings, indicating strong growth potential [36].

Group 1 - The company, KQ Bio, focuses on the research, development, production, sales, and animal epidemic prevention technology services of veterinary biological products [2] - The main products of the company include non-mandatory immunization vaccines for pigs and poultry vaccines [2]

Core Viewpoint - The company is focusing on the national strategy of reducing the use of feed protein and is collaborating with a key laboratory to develop solutions for converting agricultural organic waste into insect protein [2] Group 1: Company Initiatives - The company is working closely with the National Key Laboratory for the Exploration and Utilization of Agricultural Microbial Resources [2] - It is exploring large-scale breeding processes and automated breeding equipment for the production of insect protein from black soldier flies and microbial conversion of livestock manure and food waste [2] - A systematic solution for the large-scale conversion of agricultural organic waste using black soldier flies has been initially formed, laying the foundation for future improvement and application [2]

Core Viewpoint - The company acknowledges that its stock price is influenced by multiple factors including macroeconomic conditions, policy changes, and market sentiment [2] Group 1 - The company is committed to high-quality development and will continue to increase its investment in research and development [2] - The company aims to enhance its operational capabilities and provide returns to investors [2]

Group 1 - The core viewpoint of the article is that the company, Keqian Biotechnology, has received approval from the Ministry of Agriculture and Rural Affairs for a new veterinary drug registration certificate for a vaccine aimed at preventing diseases caused by Porcine Circovirus Type 2 [1][2] - The approved product is a recombinant virus-inactivated vaccine (CH17 strain, suspension culture) specifically designed for the prevention of Porcine Circovirus Type 2 infections [1][2] - The approval will enrich the company's product line, but the market promotion and sales situation remain uncertain until the product obtains the necessary approval number for market sales [1]

Group 1 - XianDao Intelligent has set the final price for its H-share public offering at HKD 45.8 per share, with expected listing on February 11, 2026 [1] - Jida Communication is a candidate for a project with China Mobile, with an estimated service fee of approximately CNY 51.04 million [2] - Bowei Alloy's controlling shareholder plans to increase holdings by CNY 100 million to 150 million from February 10 to August 9, 2026 [3] Group 2 - Xiamen Airport reported 16,368 aircraft takeoffs and landings in January 2026, a year-on-year decrease of 4.82%, with passenger throughput of 2.38 million, down 3.84% [4] - Yitong Century has won a bid for a project worth CNY 107 million, providing comprehensive maintenance services for China Tower [5] - Huayi Brothers' controlling shareholder's 70 million shares are subject to judicial auction, representing 42.89% of his holdings and 2.52% of the company's total shares [6] Group 3 - Lianhuan Pharmaceutical received approval for the sale of Tadalafil tablets (20mg) in Ghana [7] - Aonong Biological reported a pig sales volume of 166,600 in January 2026, a year-on-year increase of 35.36% [8] - Xiantan Co. achieved chicken product sales revenue of CNY 546 million in January 2026, a year-on-year increase of 54.9% [9] Group 4 - Zhengbang Technology reported a January sales revenue of CNY 816 million from pig sales, a year-on-year increase of 19.69% [10] - Qianjin Pharmaceutical's net profit for 2025 grew by 24.74% to CNY 288 million [11] - Xinhua Pharmaceutical received a drug registration certificate for glucosamine sulfate capsules [12] Group 5 - Yuandong Bio completed the first dosing of its EP-0210 monoclonal antibody in a Phase I clinical trial for inflammatory bowel disease [13] - Jiaokong Technology signed a contract for the Sydney Metro West Line signal system subcontracting project worth AUD 93.53 million [14] - Dangsheng Technology signed a strategic cooperation framework agreement with Huineng Technology in solid-state batteries and the new energy industry [15] Group 6 - Jinhui Co. plans to acquire 100% of Fusheng Mining for CNY 210 million [16] - Cangzhou Mingzhu announced Guangzhou Light Industry as its new controlling shareholder after a share transfer [17] - Dingxin Technology's vice president was fined CNY 120,000 for short-term trading [18][19] Group 7 - China Modern Pharmaceutical's subsidiary passed a GMP compliance inspection for its production line [20] - Chaosheng Electronics plans to increase capital by CNY 400 million in its subsidiary to enhance competitiveness [21] - Lonyu Mountain reported a 25.03% year-on-year increase in pig sales revenue in January 2026 [22] Group 8 - Sanbo Brain Science's chairman has been released from investigation, and the company is operating normally [23] - Hainan Mining is planning to acquire control of Luoyang Fengrui Fluorine Industry and will resume trading on February 10, 2026 [24] - Dongwei Technology's net profit for 2025 increased by 86.81% [25] Group 9 - Yuanjie Technology plans to invest CNY 1.251 billion in a semiconductor chip and device R&D production base [26] - Metro Design signed a contract for an energy management project with Guangzhou Metro Group worth CNY 924 million [27] - Zhongmin Energy intends to acquire 51% of Fujian Yongtai Mintou Pumped Storage Co. for CNY 864 million [28] Group 10 - Dianzhi Technology plans to repurchase shares worth CNY 100 million to 200 million [29] - China Baoan was not selected as a restructuring investor for the Singshan Group [30] - Zhiguang Electric's subsidiary signed a CNY 1.004 billion contract for energy storage systems [31] Group 11 - Zhifei Biological received approval for a clinical trial of its herpes zoster vaccine [32] - KQ Bio received a new veterinary drug registration certificate for a vaccine against porcine circovirus type 2 [33] - Huanxu Electronics reported a 4% year-on-year increase in consolidated revenue for January 2026 [34] Group 12 - Xiangjia Co. reported a 10.42% year-on-year increase in live poultry sales revenue in January 2026 [35] - Kemin Foods' subsidiary reported a 68.29% year-on-year increase in pig sales revenue in January 2026 [36] - Liyuan Technology signed a procurement contract worth CNY 54.98 million [37] Group 13 - Jiuqiang Bio received a medical device registration certificate for a fibrin degradation product detection kit [38] - Zhongguancun's subsidiary passed the consistency evaluation for Tramadol Hydrochloride tablets [39] - Rundou Co. received a drug registration certificate for Candesartan Etil [40]

证券代码：688526 证券简称：科前生物 公告编号：2026-001 武汉科前生物股份有限公司 关于获批新兽药注册证书的自愿性信息披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 根据《兽药管理条例》和《兽药注册办法》规定，经中华人民共 和国农业农村部审查，批准公司申报的猪圆环病毒 2 型重组杆状病毒 灭活疫苗（CH17 株，悬浮培养）为新兽药，并核发《新兽药注册证 书》，具体详情如下： 一、新兽药的基本信息 新兽药名称：猪圆环病毒 2 型重组杆状病毒灭活疫苗（CH17 株， 悬浮培养） 英文名：Porcine Circovirus Type 2 Recombinant Baculovirus Vaccine，Inactivated (Strain CH17, Suspension Culture) 新兽药注册证书号：（2026）新兽药证字 31 号 注册分类：三类 研制单位：武汉科前生物股份有限公司 监测期：3 年 主要成分与含量：每头份疫苗中含有表达的猪圆环病毒 2d 型 Cap 武汉科前生物股份有限公司以 ...

Core Viewpoint - The company has received approval for its recombinant inactivated vaccine for Porcine Circovirus Type 2, which will enhance its product offerings and competitiveness in the market [1] Group 1: Product Approval - The vaccine has been approved by the Ministry of Agriculture and Rural Affairs and has received the New Veterinary Drug Registration Certificate [1] - The registration classification of the vaccine is categorized as Class III, with a monitoring period of three years [1] Group 2: Vaccine Efficacy - The vaccine is intended to prevent infections caused by Porcine Circovirus Type 2, providing active immunity that lasts for four months after 28 days of administration [1] - Passive immunity for piglets lasts until 21 days of age [1] Group 3: Market Impact - The approval of the product will diversify the company's product range and enhance its competitive position in the industry [1] - However, the timeline for production and sales remains uncertain pending the acquisition of the necessary approval number [1]

Core Viewpoint - The approval of the new vaccine by the Ministry of Agriculture and Rural Affairs of the People's Republic of China represents a significant milestone for the company, enhancing its product portfolio and market competitiveness [1] Group 1: Product Development - The company has received approval for its recombinant inactivated vaccine for Porcine Circovirus Type 2 (CH17 strain, suspension culture) as a new veterinary drug [1] - This approval is in accordance with the Veterinary Drug Management Regulations and the Veterinary Drug Registration Measures [1] Group 2: Business Impact - The successful approval of the vaccine will diversify the company's product offerings, promoting a multi-faceted business development strategy [1] - The new product is expected to positively influence the company's operational growth and market competitiveness [1]

Investment Rating - The report gives an "Overweight" rating for the agricultural industry, indicating that it is expected to outperform the overall market [3][10]. Core Insights - The 2026 Central Document emphasizes food security and agricultural modernization, reiterating the importance of "new agricultural productivity" and the continuous focus on seed industry revitalization, particularly in biological breeding [4]. - In livestock, there is a shift towards "strengthening" comprehensive regulation of pig production capacity, with a focus on stabilizing the beef and dairy industries, and promoting dairy product consumption [4]. - The document highlights the importance of grain security, aiming to stabilize grain production at around 14 trillion jin, and introduces measures to enhance grain circulation efficiency [4]. - The report outlines the implementation of agricultural technology, including the integration of artificial intelligence with agriculture, and identifies key application scenarios such as drones, IoT, and robotics [4]. - The report suggests three main investment focuses: the recovery of the beef and dairy industries, the expected rebound in the pig cycle, and the continued advancement of the seed industry and biological breeding [4]. Summary by Sections Livestock Industry - The report indicates a comprehensive approach to regulating pig production capacity and acknowledges the success of measures taken to support the beef and dairy industries [4]. - It also mentions the introduction of multiple measures to promote dairy product consumption for the first time [4]. Crop Production - The focus remains on food security, with a commitment to stabilize grain production and enhance the efficiency of grain circulation [4]. - The report introduces a new round of initiatives aimed at increasing grain production capacity, particularly for oilseed crops like soybeans [4]. Seed Industry - The report emphasizes the ongoing implementation of seed industry revitalization actions and the acceleration of biological breeding industrialization [4]. - It notes the continuous mention of biological breeding in the Central Document over the past six years, highlighting its growing importance [4]. Agricultural Technology - The report outlines the path for implementing new agricultural productivity, emphasizing the need for technology integration, particularly in AI applications [4]. Agricultural Trade - The report advocates for the coordination of agricultural trade and production, promoting diversification of agricultural imports and supporting the export of competitive agricultural products [4].